Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, Chari A, Jagannath S, Koehne G. Smith E, et al. Among authors: chari a. Biol Blood Marrow Transplant. 2016 Feb;22(2):258-267. doi: 10.1016/j.bbmt.2015.08.025. Epub 2015 Aug 30. Biol Blood Marrow Transplant. 2016. PMID: 26325439 Free PMC article.
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Vogl DT, et al. Among authors: chari a. J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30. J Clin Oncol. 2018. PMID: 29381435 Free PMC article. Clinical Trial.
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Barley K, Sanchez L, Cho HJ, Parekh S, Madduri D, Richter J, Isola L, Goldstein T, Dhadwal A, Zarychta K, Sanchez GM, Catamero D, Verina D, Florendo E, Yum MH, La L, Gullie J, Chan E, Jagannath S, Chari A. Barley K, et al. Among authors: chari a. Am J Hematol. 2020 Feb;95(2):E51-E54. doi: 10.1002/ajh.25695. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31814152 Free article. Clinical Trial. No abstract available.
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: chari a. Leukemia. 2020 Sep;34(9):2430-2440. doi: 10.1038/s41375-020-0756-6. Epub 2020 Feb 24. Leukemia. 2020. PMID: 32094461 Free PMC article.
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
Jatiani SS, Aleman A, Madduri D, Chari A, Cho HJ, Richard S, Richter J, Brody J, Jagannath S, Parekh S. Jatiani SS, et al. Among authors: chari a. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32553791 Free PMC article. No abstract available.
381 results